re: The FDA has issued an Emergency Use Authorization (EUA) for Eli Lilly’s bebtelovimab

The “don’t give if admitted” policy is a flawed logic by Doctors and the hospitals. It applies to people who’ve had clinical signs for an extended period but not for newly infected patients.

The MAB’s are only effective early in the course of infection. As with any virus, Covid only replicates in the body for a set time period. During that time, the introduction of MAB’s (if properly matched to the virus variant), slow to stop virus replication and hence prevent further virus damage. They are highly effective early on in the infection. My wife (no pictures) and I had BamlanviMaB in late 2020 and it dead stopped any clinical signs.

Most people who enter the hospital are not there due to the virus alone, they are there due to comorbidities getting out of hand and/or secondary effects following the viral infection (bacterial pneumonia, systemic reactions, organ failure Etc,). These people are beyond the virus replication phase of the infection. Introduction of MAB’s at this point is usually useless and can creat the issues described worsening the situation due to immune system “stimulation”

In the patient you described, if properly matched, the MAB should have worked very well.